106 related articles for article (PubMed ID: 9893628)
1. Efficacy and toxicity of 2-Chlorodeoxyadenosine (Cladribine)--2 h infusion for 5 days--as first-line treatment for advanced low grade non-Hodgkin's lymphoma.
Fridrik MA; Jäger G; Kienzer HR; Hausmaninger H; Oppitz P; Krieger O; Zabernigg A; Lang A; Neubauer M; Weidinger G; Schiller L; Seewann HL; Chott A; Linkesch W
Eur J Cancer; 1998 Sep; 34(10):1560-4. PubMed ID: 9893628
[TBL] [Abstract][Full Text] [Related]
2. Fewer infections, but maintained antitumor activity with lower-dose versus standard-dose cladribine in pretreated low-grade non-Hodgkin's lymphoma.
Betticher DC; von Rohr A; Ratschiller D; Schmitz SF; Egger T; Sonderegger T; Herrmann R; Kroner T; Zulian GB; Cavalli F; Fey MF; Cerny T
J Clin Oncol; 1998 Mar; 16(3):850-8. PubMed ID: 9508165
[TBL] [Abstract][Full Text] [Related]
3. Reduced-dose cladribine (2-CdA) plus mitoxantrone is effective in the treatment of mantle-cell and low-grade non-Hodgkin's lymphoma.
Rummel MJ; Chow KU; Karakas T; Jäger E; Mezger J; von Grünhagen U; Schalk KP; Burkhard O; Hansmann ML; Ritzel H; Bergmann L; Hoelzer D; Mitrou PS
Eur J Cancer; 2002 Sep; 38(13):1739-46. PubMed ID: 12175690
[TBL] [Abstract][Full Text] [Related]
4. Cladribine in the treatment of advanced relapsed or refractory low and intermediate grade non-Hodgkin's lymphoma.
Tulpule A; Schiller G; Harvey-Buchanan LA; Lee M; Espina BM; Khan AU; Boswell W; Nathwani B; Levine AM
Cancer; 1998 Dec; 83(11):2370-6. PubMed ID: 9840537
[TBL] [Abstract][Full Text] [Related]
5. 2-Chlorodeoxyadenosine treatment in non-Hodgkin's lymphoma and B-cell chronic lymphocytic leukemia resistant to conventional chemotherapy: results of a multicentric experience. International Society for Chemo-Immunotherapy.
Brugiatelli M; Holowiecka B; Dmoszynska A; Krieger O; Planinc-Peraica A; Labar B; Callea V; Morabito F; Jaksic B; Holowiecki J; Lutz D
Ann Hematol; 1996 Aug; 73(2):79-84. PubMed ID: 8774616
[TBL] [Abstract][Full Text] [Related]
6. Cladribine for untreated or early low-grade non-Hodgkin's lymphoma.
Liliemark J; Martinsson U; Cavallin-Ståhl E; Svedmyr E; Porwit A; Strömberg M; Juliusson G
Leuk Lymphoma; 1998 Aug; 30(5-6):573-81. PubMed ID: 9711919
[TBL] [Abstract][Full Text] [Related]
7. Activity of 2-chlorodeoxyadenosine (Cladribine) in 2-hour intravenous infusion in 94 previously treated patients with low grade non-Hodgkin's lymphoma.
Róbak T; Gora-Tybor J; Krykowski E; Walewski JA; Borawska A; Pluźańska A; Potemski P; Hellmann A; Zaucha JM; Konopka L; Ceglarek B; Durźyński T; Sikorska A; Michalak K; Urasiński J; Opalińska J; Dmoszyńska A; Adamczyk-Cioch MB; Kuratowska Z; Dwilewicz-Trojaczek J; Boguradzki P; Deren M; Maj S; Grieb P
Leuk Lymphoma; 1997 Jun; 26(1-2):99-105. PubMed ID: 9250793
[TBL] [Abstract][Full Text] [Related]
8. Treatment of mantle-cell lymphomas with intermittent two-hour infusion of cladribine as first-line therapy or in first relapse.
Rummel MJ; Chow KU; Jäger E; Hossfeld DK; Bergmann L; Peters HD; Hansmann ML; Meyer A; Hoelzer D; Mitrou PS
Ann Oncol; 1999 Jan; 10(1):115-7. PubMed ID: 10076731
[TBL] [Abstract][Full Text] [Related]
9. Intermittent 2-hour-infusion of cladribine as first-line therapy or in first relapse of progressive advanced low-grade and mantle cell lymphomas.
Rummel MJ; Chow KU; Jäger E; Leimer L; Hossfeld DK; Bergmann L; Peters HD; Hansmann ML; Meyer A; Hoelzer D; Mitrou PS
Leuk Lymphoma; 1999 Sep; 35(1-2):129-38. PubMed ID: 10512170
[TBL] [Abstract][Full Text] [Related]
10. The multicenter trial SAKK 37/95 of cladribine, cyclophosphamide and prednisone in the treatment of chronic lymphocytic leukemias and low-grade non-Hodgkin's lymphomas.
Laurencet F; Ballabeni P; Rufener B; Hess U; Cerny T; Fey M; Luthi JM; Plancherel C; Zulian GB;
Acta Haematol; 2007; 117(1):40-7. PubMed ID: 17095858
[TBL] [Abstract][Full Text] [Related]
11. Long term follow-up and late complications of 2-chlorodeoxyadenosine in previously treated, advanced, indolent non-Hodgkin's lymphoma.
Kong LR; Huang CF; Hakimian D; Variakojis D; Klein L; Kuzel TM; Gordon LI; Zanzig C; Wollins E; Tallman MS
Cancer; 1998 Mar; 82(5):957-64. PubMed ID: 9486587
[TBL] [Abstract][Full Text] [Related]
12. Cladribine treatment in two-hour intravenous infusion for previously-treated low grade B-cell lymphoma: a pilot study.
Takamatsu Y; Suzumiya J; Ogata K; Katayose K; Sasaki H; Ishitsuka K; Kimura N; Tamura K
J Clin Exp Hematop; 2009 Nov; 49(2):69-75. PubMed ID: 19907111
[TBL] [Abstract][Full Text] [Related]
13. Long-term results of a multicentre randomised, comparative phase III trial of CHOP versus CNOP regimens in patients with intermediate- and high-grade non-Hodgkin's lymphomas. Novantrone International Study Group.
Bezwoda W; Rastogi RB; Erazo Valla A; Diaz-Maqueo JC; Pavlovsky S; Morioka H; Resegotti L; Rueckle H; Somoza N; Moreno-Nogueira JA
Eur J Cancer; 1995 Jun; 31A(6):903-11. PubMed ID: 7646919
[TBL] [Abstract][Full Text] [Related]
14. Durable response but prolonged cytopenia after cladribine treatment in relapsed patients with indolent non-Hodgkin's lymphomas: results of a Japanese phase II study.
Ogura M; Morishima Y; Kobayashi Y; Uike N; Sugai S; Chou T; Kasai M; Miura I; Murayama T; Matsuno Y; Nakamura S; Mori S; Ohashi Y; Tobinai K;
Int J Hematol; 2004 Oct; 80(3):267-77. PubMed ID: 15540903
[TBL] [Abstract][Full Text] [Related]
15. High response rates with short infusional 2-chlorodeoxyadenosine in de novo and relapsed low-grade lymphoma. Australian and New Zealand Lymphoma Study Group.
Morton J; Taylor K; Bunce I; Eliadis P; Rentoul A; Moore D; Kelly C; Wright S; Bashford J; Rodwell R; Rooney K; Mulligan S; Firkin F; Dodds A; Parkin J; Lowenthal R; Kimber R; Frost T; Grigg A; Goldstein D; Stone J; Lee N
Br J Haematol; 1996 Oct; 95(1):110-5. PubMed ID: 8857946
[TBL] [Abstract][Full Text] [Related]
16. Phase I study of cladribine (2-chlorodeoxyadenosine) in lymphoid malignancies. Cladribine Study Group.
Tobinai K; Ogura M; Hotta T; Kobayashi Y; Narabayashi M; Suzuki R; Kinoshita T; Kozuru M; Uike N; Ohashi Y
Jpn J Clin Oncol; 1997 Jun; 27(3):146-53. PubMed ID: 9255268
[TBL] [Abstract][Full Text] [Related]
17. 2-Chlorodeoxyadenosine is an active salvage therapy in advanced indolent non-Hodgkin's lymphoma.
Hoffman M; Tallman MS; Hakimian D; Janson D; Hogan D; Variakogis D; Kuzel T; Gordon LI; Rai K
J Clin Oncol; 1994 Apr; 12(4):788-92. PubMed ID: 7908690
[TBL] [Abstract][Full Text] [Related]
18. Cladribine combined with cyclophosphamide and mitoxantrone is an active salvage therapy in advanced non-Hodgkin's lymphoma.
Robak T; Lech-Maranda E; Janus A; Blonski J; Wierzbowska A; Gora-Tybor J
Leuk Lymphoma; 2007 Jun; 48(6):1092-101. PubMed ID: 17577772
[TBL] [Abstract][Full Text] [Related]
19. Reduced dose of subcutaneous cladribine induces identical response rates but decreased toxicity in pretreated chronic lymphocytic leukaemia. Swiss Group for Clinical Cancer Research (SAKK).
Betticher DC; Ratschiller D; Hsu Schmitz SF; von Rohr A; Hess U; Zulian G; Wernli M; Tichelli A; Tobler A; Fey MF; Cerny T
Ann Oncol; 1998 Jul; 9(7):721-6. PubMed ID: 9739437
[TBL] [Abstract][Full Text] [Related]
20. High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin's-lymphomas.
Bremer K
J Cancer Res Clin Oncol; 2002 Nov; 128(11):603-9. PubMed ID: 12458340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]